Table 4. Serum CA125, HE4 and ROMA levels according to histology, FIGO stage and tumour grade.
|
CA125 (U ml−1)
|
HE4 (pM)
|
ROMA (%)
|
||||
|---|---|---|---|---|---|---|
| Median | IR | Median | IR | Median | IR | |
| Benign histology | 12.8 | 8.0–27.6 | 45.4 | 35.6–60.8 | 6.8 | 3.9–11.9 |
| Cystadenoma/cystadenofibroma | 11.3 | 7.4–19.5 | 53.7 | 40.8–68.0 | 9.1 | 5.7–14.4 |
| Endometriosis | 25.5 | 10.7–54.9 | 40.0 | 34.3–50.7 | 4.9 | 3.3–7.5 |
| Fibroma/thecoma | 29.1 | 11.6–45.5 | 48.1 | 33.9–73.2 | 11.6 | 5.0–24.7 |
| Functional cyst | 10.5 | 6.8–20.7 | 43.7 | 30.8–54.6 | 6.2 | 3.0–9.4 |
| Mature teratoma | 9.8 | 5.7–15.9 | 43.9 | 37.5–52.5 | 5.6 | 3.4–10.9 |
| Malignant histology | 276.5 | 52.4–1195.9 | 151.8 | 67.4–560.4 | 76.1 | 25.7–96.5 |
| Epithelial ovarian cancer | 321.3 | 50.2–1291.4 | 184.6 | 72.9–589.3 | 79.6 | 28.1–96.7 |
| Metastatic | 222.9 | 64.9–913.5 | 103.5 | 48.9–302.4 | 55.0 | 9.7–92.5 |
| FIGO stage | ||||||
| I | 38.4 | 16.9–182.6 | 73.2 | 52.6–126.5 | 25.6 | 11.8–64.3 |
| II | 60.2 | 20.6–254.8 | 69.0 | 44.3–152.6 | 45.5 | 26.1–56.2 |
| III | 757.3 | 227.9–1640.0 | 308.0 | 135.0–712.5 | 91.2 | 70.3–98.4 |
| IV | 1260.7 | 790.6–2905.1 | 578.7 | 274.6–2612.9 | 98.0 | 93.0–99.5 |
| Tumour grade | ||||||
| Borderline | 38.3 | 14.8–170.4 | 67.6 | 52.6–116.4 | 23.4 | 10.0–50.1 |
| Grade 1 | 379.4 | 83.2–1120.4 | 119.9 | 72.7–336.5 | 74.5 | 52.2–94.9 |
| Grade 2 | 755.7 | 124.2–945.4 | 552.9 | 125.0–844.3 | 94.3 | 67.8–97.6 |
| Grade 3 | 748.7 | 112.1–1580.9 | 274.6 | 97.8–716.7 | 90.3 | 59.2–98.4 |
Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; HE4=human epididymis secretory protein 4; IR=interquartile range; ROMA=Risk of Ovarian Malignancy Algorithm.